Cellectis SA
CLLS3.060USD
+0.110+3.72%
시장 운영 시간 （ET）시세는 15분 지연됩니다
220.59M시가총액
손실P/E TTM
자세한 내용은 Cellectis SA 회사
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
회사 정보
종목 코드 CLLS
회사 이름Cellectis SA
상장일Feb 06, 2007
CEODr. David Sourdive, Ph.D.
직원 수224
유형Depository Receipt
회계 연도 종료Feb 06
주소8, rue de la Croix Jarry
도시PARIS
증권 거래소NASDAQ Global Market Consolidated
국가France
우편 번호75013
전화33181691600
웹사이트https://www.cellectis.com/
종목 코드 CLLS
상장일Feb 06, 2007
CEODr. David Sourdive, Ph.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Andre C. Muller
Mr. Andre C. Muller
Director
Director
--
--
Dr. Adrian Kilcoyne, M.D.
Dr. Adrian Kilcoyne, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Ms. Kyung Nam-Wortman
Ms. Kyung Nam-Wortman
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
--
--
Mr. Axel-Sven Malkomes
Mr. Axel-Sven Malkomes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Non-Executive Director
Non-Executive Director
--
--
Dr. Cecile Chartier, Ph.D.
Dr. Cecile Chartier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Andre C. Muller
Mr. Andre C. Muller
Director
Director
--
--
Dr. Adrian Kilcoyne, M.D.
Dr. Adrian Kilcoyne, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Ms. Kyung Nam-Wortman
Ms. Kyung Nam-Wortman
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
--
--
수익 분석
통화: USD마지막 업데이트: Sun, Jul 6
통화: USD마지막 업데이트: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
데이터 없음
지역별USD
이름
수익
비율
France
41.51M
0.00%
Other
0.00
0.00%
USA
0.00
0.00%
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Mon, May 26
마지막 업데이트: Mon, May 26
주주
주주 유형
주주
주주
비율
Long Focus Capital Management LLC
6.53%
B Group, Inc.
4.50%
UBS Asset Management (Switzerland)
3.98%
Pfizer Inc
3.86%
UBS Asset Management (Americas) LLC
2.55%
Other
78.58%
주주
주주
비율
Long Focus Capital Management LLC
6.53%
B Group, Inc.
4.50%
UBS Asset Management (Switzerland)
3.98%
Pfizer Inc
3.86%
UBS Asset Management (Americas) LLC
2.55%
Other
78.58%
주주 유형
주주
비율
Investment Advisor
14.08%
Hedge Fund
6.68%
Corporation
3.86%
Investment Advisor/Hedge Fund
0.49%
Research Firm
0.18%
Bank and Trust
0.04%
Pension Fund
0.01%
Other
74.66%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
78
18.32M
25.34%
-2.37M
2025Q1
83
18.44M
25.50%
-2.58M
2024Q4
88
17.72M
24.57%
+1.29M
2024Q3
106
16.31M
22.62%
-2.61M
2024Q2
105
14.76M
20.47%
-2.65M
2024Q1
113
14.77M
20.56%
-2.69M
2023Q4
124
14.69M
20.46%
-8.13M
2023Q3
142
13.62M
24.51%
-10.91M
2023Q2
155
16.13M
29.02%
-9.56M
2023Q1
162
17.33M
31.20%
-2.13M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Long Focus Capital Management LLC
4.72M
6.53%
+100.00K
+2.17%
Mar 31, 2025
B Group, Inc.
3.26M
4.5%
+175.00K
+5.68%
Mar 31, 2025
UBS Asset Management (Switzerland)
2.88M
3.98%
+1.44M
+100.00%
Mar 31, 2025
Pfizer Inc
2.79M
3.86%
+2.79M
--
Dec 31, 2023
UBS Asset Management (Americas) LLC
1.85M
2.55%
+1.85M
--
Mar 31, 2025
UBS Asset Management Switzerland AG
1.44M
1.99%
--
--
Jan 31, 2025
Macquarie Investment Management
226.88K
0.31%
--
--
Mar 31, 2025
Bellecapital AG
226.07K
0.31%
--
--
Nov 30, 2024
Baillie Gifford & Co.
139.05K
0.19%
-151.38K
-52.12%
Mar 31, 2025
Millennium Management LLC
103.85K
0.14%
-430.70K
-80.57%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
ActivePassive International Equity ETF
0%
Avantis International Equity ETF
0%
ActivePassive International Equity ETF
비율0%
Avantis International Equity ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
